CURE.DE vs. XUHC.DE
CURE.DE (VanEck Genomics and Healthcare Innovators UCITS ETF A) and XUHC.DE (Xtrackers MSCI USA Health Care UCITS ETF 1D) are both Health & Biotech Equities funds - CURE.DE tracks the MVIS Global Future Healthcare ESG while XUHC.DE tracks the MSCI USA Health Care. Both are passively managed. Over the past 3 years, CURE.DE returned -2.48%/yr vs 3.62%/yr for XUHC.DE. A 0.52 correlation means they provide meaningful diversification when combined. CURE.DE charges 0.35%/yr vs 0.12%/yr for XUHC.DE.
Performance
CURE.DE vs. XUHC.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE.DE achieves a -5.10% return, which is significantly lower than XUHC.DE's -1.34% return.
CURE.DE
- 1D
- 4.01%
- 1M
- 6.73%
- YTD
- -5.10%
- 6M
- -8.62%
- 1Y
- 6.04%
- 3Y*
- -2.48%
- 5Y*
- —
- 10Y*
- —
XUHC.DE
- 1D
- 2.83%
- 1M
- 5.38%
- YTD
- -1.34%
- 6M
- -1.19%
- 1Y
- 12.86%
- 3Y*
- 3.62%
- 5Y*
- 6.62%
- 10Y*
- —
CURE.DE vs. XUHC.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | -5.10% | 5.09% | 0.30% | -6.42% | -4.35% |
XUHC.DE Xtrackers MSCI USA Health Care UCITS ETF 1D | -1.34% | 1.47% | 8.81% | -0.83% | 1.02% |
Correlation
The correlation between CURE.DE and XUHC.DE is 0.56, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.56 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.49 |
Correlation (All Time) Calculated using the full available price history since Sep 8, 2022 | 0.52 |
The correlation between CURE.DE and XUHC.DE has been stable across timeframes, ranging from 0.49 to 0.56 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.DE vs. XUHC.DE — Risk / Return Rank
CURE.DE
XUHC.DE
CURE.DE vs. XUHC.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and Xtrackers MSCI USA Health Care UCITS ETF 1D (XUHC.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CURE.DE | XUHC.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.56 | ||
| Sortino ratioReturn per unit of downside risk | -0.79 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.15 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 1.10 | -0.79 |
| Martin ratioReturn relative to average drawdown | 0.68 | 2.69 | -2.01 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CURE.DE | XUHC.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.29 | 0.85 | -0.56 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.45 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.14 | 0.56 | -0.70 |
Drawdowns
CURE.DE vs. XUHC.DE - Drawdown Comparison
The maximum CURE.DE drawdown since its inception was -34.80%, which is greater than XUHC.DE's maximum drawdown of -26.87%. Use the drawdown chart below to compare losses from any high point for CURE.DE and XUHC.DE.
Loading charts...
Drawdown Indicators
| CURE.DE | XUHC.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.80% | -26.87% | -7.93% |
Max Drawdown (1Y)Largest decline over 1 year | -19.07% | -11.18% | -7.89% |
Max Drawdown (3Y)Largest decline over 3 years | -29.32% | -22.19% | -7.13% |
Max Drawdown (5Y)Largest decline over 5 years | — | -22.19% | — |
Current DrawdownCurrent decline from peak | -15.66% | -7.48% | -8.18% |
Average DrawdownAverage peak-to-trough decline | -15.12% | -5.08% | -10.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.53% | 4.57% | +3.96% |
Volatility
CURE.DE vs. XUHC.DE - Volatility Comparison
VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) has a higher volatility of 5.73% compared to Xtrackers MSCI USA Health Care UCITS ETF 1D (XUHC.DE) at 5.19%. This indicates that CURE.DE's price experiences larger fluctuations and is considered to be riskier than XUHC.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.DE | XUHC.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.73% | 5.19% | +0.54% |
Volatility (6M)Calculated over the trailing 6-month period | 15.20% | 10.17% | +5.03% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.97% | 14.51% | +5.46% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.74% | 14.42% | +6.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.74% | 16.13% | +4.61% |
CURE.DE vs. XUHC.DE - Expense Ratio Comparison
CURE.DE has a 0.35% expense ratio, which is higher than XUHC.DE's 0.12% expense ratio.
Dividends
CURE.DE vs. XUHC.DE - Dividend Comparison
CURE.DE has not paid dividends to shareholders, while XUHC.DE's dividend yield for the trailing twelve months is around 1.28%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XUHC.DE Xtrackers MSCI USA Health Care UCITS ETF 1D | 1.28% | 1.29% | 1.21% | 1.86% | 1.63% | 0.82% | 1.13% | 0.96% | 0.55% |
Frequently Asked Questions
CURE.DE and XUHC.DE have a correlation of 0.56, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, XUHC.DE is cheaper at 0.12% per year. The better choice depends on whether you care most about return, fees, risk, or income.
XUHC.DE is cheaper with a 0.12% expense ratio, compared with 0.35% for CURE.DE.
CURE.DE tracks MVIS Global Future Healthcare ESG, while XUHC.DE tracks MSCI USA Health Care. They also come from different issuers: VanEck and Xtrackers. Their fees differ too: 0.35% for CURE.DE and 0.12% for XUHC.DE.
Find the right allocation for CURE.DE and XUHC.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer